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Introduction
Ventilatory strategies in pediatric intensive care are fre-
quently based on strategies developed in adult or neonatal
intensive care units [1]. Recently two new ventilatory tech-
niques with almost identical names have been developed
for adults: BiPAP® and BIPAP. BiPAP® is a trade name
derived from ‘bi-level positive airway pressure’. BiPAP®
delivers, by mask, two levels of pressure in response to
patient flow. It is intended to support ventilation in a nonin-
vasive way in spontaneously but insufficiently breathing
patients in the home care environment [2,3]. In contrast,
BIPAP (biphasic positive airway pressure) is a mode of
ventilation developed for full ventilatory support in inten-
sive care settings with the use of an endotracheal tube.
This paper is about BIPAP; in US literature, BIPAP is also
known as PeV+. BIPAP uses cycling variations between
two continuous positive airway pressure levels, allowing
spontaneous breathing during every ventilatory phase
[4–6]. In adults this mode of ventilation results in effective
ventilation at lower inspiratory peak pressure levels, in less
ventilation–perfusion mismatch, and in less dead-space
ventilation [7]. Because of the ability to breathe sponta-
neously during every ventilatory phase, ventilation is being
ASB = assisted spontaneous breathing; BIPAP = biphasic positive airway pressure; PRISM, paediatric risk of mortality.
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Abstract
Background: Biphasic positive airway pressure (BIPAP) (also known as PeV+) is a mode of ventilation
with cycling variations between two continuous positive airway pressure levels. In adults this mode of
ventilation is effective and is being accepted with a decrease in need for sedatives because of the
ability to breathe spontaneously during the entire breathing cycle. We studied the use of BIPAP in
infants and children.
Methods: We randomized 18 patients with respiratory failure for ventilation with either BIPAP (n = 11)
or assisted spontaneous breathing (ASB) (n = 7) on Evita 4. Lorazepam and, if necessary, morphine
were used as sedatives and adjusted in accordance with the Comfort scale. We compared number of
randomized mode failure, duration and complications of ventilation and number and dosages of
sedatives administered.
Results: No differences in patient characteristics, ventilatory parameters, complications of ventilation
or use of sedatives were noted. Ten out of eleven patients that we intended to ventilate with BIPAP
were successfully ventilated with BIPAP. Four out of seven patients that we intended to ventilate with
ASB could not be ventilated adequately with ASB but were successfully crossed over to BIPAP
without the need for further sedatives.
Conclusions: BIPAP is an effective, safe and easy to use mode of ventilation in infants and children.
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accepted with a decreased need for sedatives [8,9].
BIPAP can be used during the entire period of artificial
ventilation, including the weaning process, by prolonging
the periods of low pressure level [5,10,11].
Better acceptance of ventilation, resulting in a decreased
need for sedatives, would be advantageous in the ventila-
tion of children. Increased work of breathing might be a
problem in children when BIPAP is used in the weaning
phase because of a prolongation of periods of low pres-
sure levels.
No studies with BIPAP have been performed in children
until now. We performed a study to determine whether
BIPAP is an effective, safe and easy to use mode of venti-
lation in children, resulting in a decreased need for seda-
tives.
Methods
Patients and protocols
We had intended to compare BIPAP with pressure
support ventilation [assisted spontaneous breathing
(ASB)] with the use of Evita 4 (Dräger, Lübeck, Germany)
in 25 patients each. However, soon after the introduction
of Evita 4 on the ward, physicians and nurses preferred
the use of BIPAP over ASB, and inclusion of patients
stopped. We therefore studied a total of 18 patients
admitted to the Pediatric Intensive Care Unit of the Univer-
sity Hospital of Groningen. Exclusion criteria were: weight
less than 3000 g, cyanotic heart disease or neuromuscu-
lar disease. Randomization was performed by the coin
method and took place when paralysis, used for intuba-
tion, had been resolved. Initial ventilator settings
depended on age and the reason for respiratory failure,
and were adjusted according to thoracic excursions and
measured tidal volume. Adjustments were made after-
wards aiming at a pCO2 of 4–5 kPa and a pO2 of
8–11 kPa.
Sedatives were given in accordance with the Comfort
scale (Table 1), which is a nonintrusive measure for
assessing distress in pediatric intensive care patients, with
high inter-rater agreement and high internal consistency
[12]. Good sedation is obtained when the total score is
between 17 and 26. The Comfort scale was obtained by
trained nurses at 2 h intervals for the first 24 h after intuba-
Table 1
Comfort scale [12]
Score
Variable 1 2 3 4 5
Alertness Deeply asleep Lightly asleep Drowsy Fully awake and alert Hyper alert
Calmness/agitation Calm Slightly anxious Anxious Very anxious Panicky
Respiratory response No coughing and  Spontaneous  Occasional cough  Actively breathes  Fights ventilator, 
no spontaneous  respiration with little  or resistance to  against ventilator or  coughing or choking
respiration or no response to  ventilator coughs regularly
ventilation
Physical movement No movement Occasional, slight  Frequent, slight  Vigorous movement  Vigorous movements 
movement movements limited to extremities including torso and 
head
Mean arterial  Blood pressure  Blood pressure  Infrequent elevations  Frequent elevations of  Sustained elevation 
blood pressure below baseline consistently at  of 15% or more  15% or more above  of 15% or more 
baseline (1–3 during   baseline (more than 3 
observation period) during observation 
period)
Heart rate Heart rate below  Heart rate  Infrequent elevations  Frequent elevations of  Sustained elevation 
baseline consistently at  of 15% or more  15% or more above  of 15% or more 
baseline above baseline (1–3  baseline (more than 3 
during observation  during observation 
period) period) 
Muscle tone Muscle totally  Reduced muscle tone Normal muscle tone Increased muscle tone  Extreme muscle 
relaxed, no muscle  and flexion of fingers  rigidity
tone and toes
Facial tension Facial muscles  Facial muscle tone  Tension evident in  Tension evident  Facial muscles 
totally relaxed normal, no facial  some facial muscles throughout facial  contorted and 
muscle tension evident  muscles grimacingCritical Care    Vol 5 No 3 Jaarsma et al
tion, and afterwards at 6 h intervals. Lorazepam
(0.4 mg/kg in four divided doses) was used as sedative.
To keep the Comfort scale score between 17 and 26, the
lorazepam dose was adjusted as needed to a maximum of
0.6 mg/kg in six divided doses. If more sedatives were
needed, morphine was added at a loading dose of
100 mg/kg and a maintenance dose of 10–20 mg/kg per
hour. Randomized mode failure was recorded if, despite
optimal ventilatory settings and the optimal use of seda-
tives, the patient could not be ventilated adequately. The
patient was then transferred to the other study ventilatory
mode; if neither succeeded, the study was stopped.
The recorded patient characteristics were age, weight,
gender, diagnosis and paediatric risk of mortality (PRISM)
score. The recorded ventilatory parameters were ventila-
tory mode, duration of ventilation, and complications of
ventilation (atelectasis or accidental extubation). Regis-
tered parameters for adequacy of sedation were the
Comfort scale and the number and dosage of sedatives.
The following endpoints of the study were considered:
number of patients transferred to the alternative ventilatory
mode because of inadequate ventilation or high Comfort
scale despite maximal sedative use according to study
protocol, complications of ventilation, and number and
dosage of sedatives administered.
Statistical analysis
Continuous and ordinal variables were checked for normal
distribution with one sample Kolmogorov–Smirnov test.
Age and weight were not normally distributed and were
analysed for statistical significant differences with the two-
sample Kolmogorov–Smirnov test for small numbers.
PRISM score, duration of ventilation, lorazepam dosage
and morphine dosage were normally distributed and were
analysed for statistically significant differences with the
independent-samples t-test. Fisher’s exact test was used
to analyse whether statistically significant numbers of
patients experienced randomized mode failure or needed
the addition of morphine as a sedative.
Results
Eighteen patients were included. Reasons for respiratory
failure were diverse. In the BIPAP group, five patients
were ventilated postoperatively, four patients were venti-
lated because of infection, one patient was ventilated
because of pulmonary hypertension accompanying
Table 2
Patient characteristics
Characteristic BIPAP (n = 11) ASB (n = 7) Significance
Age* 4 mo (6 wk to 21months) 4 mo (4 weeks to 10 years) P = 0.88
Weight* 5125 g (3300 g to 13.5 kg) 5150 g (3925 g to 27 kg) P = 0.88
Numbers of each gender 5 male, 6 female 5 male, 2 female
PRISM score* 2 (0–17) 6 (0–17) P = 0.81
*Median and range.
Table 3
Ventilatory parameters and use of sedatives
Parameter BIPAP (n = 11) ASB (n = 7) Significance
Randomized mode failure (no.) 1† 4  P = 0.047
Duration of ventilation (days)* 9.8 ± 9.2 6.4 ± 5.8 P = 0.27
Atelectasis (no.) 5  3 P = 1.0
Accidental extubation (no.) 1  0  P = 1.0
Sedatives
Lorazepam (all), dosage (mg/kg per day)* 0.43 ± 0.12) 0.46 ± 0.16 P = 0.76
Morphine added(no.) 8‡ 4  P = 0.63
Dosage (mg/kg per h)* 9.34 ± 7.32 6.61 ± 7.10 P = 0.45
*Data are shown as means±SD. †In this patient, after transfer, ASB did not succeed either. The infant was ventilated with Babylog 8000. 
‡In two patients midazolam was also added, at 100–200 mg/kg per h.cardiac disease, and one patient was ventilated because
of obstruction of the upper airway. In the ASB group, two
patients were ventilated postoperatively, three patients
were ventilated because of infection, one patient was ven-
tilated because of pulmonary hypertension accompanying
cardiac disease, and one patient was ventilated because
of obstruction of the upper airway. Patient characteristics
are described in Table 2; ventilatory parameters and the
use of sedatives are shown in Table 3.
No differences in patient characteristics, duration of venti-
lation, complications of ventilation or need for sedatives
were noted.
After randomization, we intended to treat eleven patients
with BIPAP, which succeeded in ten patients. The one
patient that could not be ventilated with BIPAP was trans-
ferred to ASB, which did not succeed either. Afterwards
the infant was successfully ventilated with Babylog 8000
(Dräger). Eight of the eleven patients needed the addition
of morphine for adequate sedation.
We had intended to treat seven patients with ASB, which
succeeded in three patients. The four patients that could
not be ventilated with ASB were transferred to BIPAP,
which succeeded in all of them. These four patients
needed the addition of morphine for adequate sedation
during ASB, but during BIPAP no sedatives were added.
Discussion
BIPAP is a new mode of artificial ventilation that has been
used successfully in adult patients. In adults this ventila-
tory mode results in a shorter duration of ventilation, a
decreased need for sedatives and fewer complications in
comparison with pressure controlled or pressure sup-
ported ventilation [4]. We demonstrated in the present
study that BIPAP can be used safely and effectively in
infants and children. We found no differences in the dura-
tion of ventilation, in the incidence of complications or in
the use of sedatives in comparison with ASB. However,
ventilation with ASB resulted in a significantly greater
number of randomized mode failures than ventilation with
BIPAP, and transfer to BIPAP resulted in successful venti-
lation without the need for added sedatives in all patients.
We therefore believe that BIPAP might be advantageous
over ASB.
However, from this study we cannot conclude that BIPAP
is a better mode of ventilation for infants and children with
a decreased need of sedatives than other modes of venti-
lation: the number of patients included was too small. We
had planned to include more patients, but soon after intro-
duction of Evita 4 on the ward, physicians and nurses pre-
ferred to use BIPAP over ASB and the patients’ inclusion
in the study stopped. The reasons for this preference of
people on the ward for BIPAP could be one or more of the
following: a preference for the newest mode of ventilation,
the increased rate of randomized mode failure in the ASB
group, or the possibility of using BIPAP during the entire
period of artificial ventilation without the necessity to
switch between ventilatory modes when patients are
paralysed or when weaning is initiated. To exclude those
possible biases one would have to to perform a blinded
study.
We conclude that BIPAP is an effective, safe and easy to
use mode of ventilation in infants and children. Its use for
ventilation of infants and children during the entire period
of artificial ventilation makes this mode of ventilation suit-
able for use in training hospitals.
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